4-Biphenylcarboxylic Acid (92-92-2) Hiki Mai Hou

Me kā mākou hoʻokele koʻikoʻi, ka mana ʻenehana ikaika a me ke kaʻina hana koʻikoʻi koʻikoʻi, hoʻomau mākou e hāʻawi i kā mākou mea kūʻai aku me ka maikaʻi maikaʻi kūpono, nā kumukūʻai kūʻai kūpono a me nā lawelawe maikaʻi loa.Manaʻo mākou e lilo i hoʻokahi o kāu mau hoa kuleana nui a loaʻa i kou hauʻoli no Newly Arrival 4-Biphenylcarboxylic Acid (92-92-2), ʻO ke kumu o kā mākou hui e hāʻawi mau i nā mea kūʻai kiʻekiʻe, lawelawe loea, a me ka kamaʻilio pololei. .Welina mai e nā hoaaloha a pau e hoʻokolokolo no ka hana ʻana i kahi hui ʻoihana lōʻihi.
Me kā mākou hoʻokele koʻikoʻi, ka mana ʻenehana ikaika a me ke kaʻina hana koʻikoʻi koʻikoʻi, hoʻomau mākou e hāʻawi i kā mākou mea kūʻai aku me ka maikaʻi maikaʻi kūpono, nā kumukūʻai kūʻai kūpono a me nā lawelawe maikaʻi loa.Manaʻo mākou e lilo ʻoiaʻiʻo i hoʻokahi o kāu mau hoa kuleana nui a loaʻa iā ʻoe kou hauʻoliKina Organic Synthesis Intermediates, Hoʻokuʻu nui ʻia kā mākou mea kūʻai aku i ka Hikina Hema, ka Middle East, ʻAmelika ʻAmelika a me ʻEulopa.ʻO kā mākou maikaʻi ʻoiaʻiʻo.Inā makemake ʻoe i kekahi o kā mākou waiwai a makemake paha e kūkākūkā i kahi kauoha maʻamau, e ʻoluʻolu e hoʻokaʻaʻike mai iā mākou.Ke kakali nei mākou i ka hoʻokumu ʻana i nā pilina ʻoihana kūleʻa me nā mea kūʻai aku hou a puni ka honua i ka wā e hiki mai ana.

Hoʻohana ʻia ka 2'-hydroxy-3′-nitro-3-biphenylcarboxylic acid ma ke ʻano he waena o Eltrombopag.
ʻO Eltrombopag, i hoʻomohala ʻia e GlaxoSmithKline (GSK) ma UK a ma hope i hoʻomohala pū ʻia me Novartis ma Switzerland, ʻo ia ka mea mua a ʻae wale ʻia ka mole liʻiliʻi non peptide TPO receptor agonist ma ka honua.Ua ʻae ʻia ʻo Eltrombopag e ka US FDA ma 2008 no ka mālama ʻana i ka idiopathic thrombocytopenic purpura (ITP), a ma 2014 no ka mālama ʻana i ka anemia aplastic koʻikoʻi (AA).ʻO ia ka lāʻau lapaʻau mua i ʻae ʻia e ka US FDA no ka mālama ʻana iā AA i nā makahiki he 30 i hala iho nei.
Ma December2012, ua apono ka US FDA ia Eltrombopag no ka lapaau ana i ka thrombocytopenia i na ma'i me ka ma'i hepa C (CHC), i hiki i na ma'i hepa C me ka ilihune prognosis ma muli o ka helu platelet ha'aha'a hiki ke ho'omaka a mālama i ka interferon ma muli o ka ma'i ma'i o ka ate.Ma Feberuari 3,2014, ua hoʻolaha ʻo GlaxoSmithKline ua hāʻawi ka FDA i ka hōʻailona lāʻau lapaʻau holomua o Eltrombopag no ka mālama ʻana i ka hemopenia i nā maʻi me ka puke kemika aplastic anemia (SAA) ʻaʻole i pane piha i ka immunotherapy.Ma ʻAukake 24, 2015, ua ʻae ka US FDA iā Eltrombopag no ka mālama ʻana i ka thrombocytopenia i nā pākeke a me nā keiki o 1 makahiki a ʻoi aku me ka thrombocytopenia immune maʻi (ITP) i lawa ʻole ka pane ʻana i nā corticosteroids, immunoglobulins a splenectomy.Ma Ianuali4,2018, ua ʻae ʻia ʻo Eltrombopag e papa inoa ma Kina no ka mālama ʻana i ka thrombocytopenia immune mua (ITP).

Me kā mākou hoʻokele koʻikoʻi, ka mana ʻenehana ikaika a me ke kaʻina hana koʻikoʻi koʻikoʻi, hoʻomau mākou e hāʻawi i kā mākou mea kūʻai aku me ka maikaʻi maikaʻi kūpono, nā kumukūʻai kūʻai kūpono a me nā lawelawe maikaʻi loa.Manaʻo mākou e lilo i hoʻokahi o kāu mau hoa kuleana nui a loaʻa i kou hauʻoli no Newly Arrival 4-Biphenylcarboxylic Acid (92-92-2), ʻO ke kumu o kā mākou hui e hāʻawi mau i nā mea kūʻai kiʻekiʻe, lawelawe loea, a me ka kamaʻilio pololei. .Welina mai e nā hoaaloha a pau e hoʻokolokolo no ka hana ʻana i kahi hui ʻoihana lōʻihi.
Hiki HouKina Organic Synthesis Intermediates, Hoʻokuʻu nui ʻia kā mākou mea kūʻai aku i ka Hikina Hema, ka Middle East, ʻAmelika ʻAmelika a me ʻEulopa.ʻO kā mākou maikaʻi ʻoiaʻiʻo.Inā makemake ʻoe i kekahi o kā mākou waiwai a makemake paha e kūkākūkā i kahi kauoha maʻamau, e ʻoluʻolu e hoʻokaʻaʻike mai iā mākou.Ke kakali nei mākou i ka hoʻokumu ʻana i nā pilina ʻoihana kūleʻa me nā mea kūʻai aku hou a puni ka honua i ka wā e hiki mai ana.